Dear Partners,

Necessitated by the unprecedented situation created by Covid-19, several industry events and tradeshows across the world have been postponed or stand cancelled. While we were looking forward to meet you, we at Piramal Pharma Solutions have had to take several precautionary measures to protect both our employees and customers, worldwide.

As we move forward in these extraordinary times, we want to assure you that that we are operational by taking the right safety measures and abundant precautions to ensure that we continue to support you and your patients.

While all of us are working remotely for now, you can schedule a discussion with us and we would be glad to help ensure you meet your pharmaceutical development and supply needs and thereby, your clinical and commercial timelines.

Please feel free to reach out to us at:

Our best wishes to colleagues, friends and family.

Best Regards,
Piramal Pharma Solutions

PiramalPharma Solutions Logo

Route Scouting

We assist our partners in developing cost effective, competitively advantaged, and robust chemical processes that emphasize atom efficiency and minimize waste.

A few challenges that we have previously addressed includes the following:

  • I have a medicinal chemistry route; I need to make 100--250 gms for GLP Tox studies
  • I need a robust route for Tox/Ph I; my route uses reagents that are expensive OR not available in bulk
  • My route uses toxic or hard to handle reagents
  • I have multiple chromatographic separations leading to significant loss in yields
  • I am going to face generic competition and need a cost effective route at scale to be competitive
  • I want to reduce the number of steps, or decrease the cycle time to release capacity
  • I want non-infringing route

Route Scouting Process Flow

  • Bespoke service to provide scalable routes leveraging Piramal Process Chemistry expertise globally and India based execution
  • Rapid access to targeted scaffold structures
  • Focus on speed and initial delivery of gram quantities
  • Reduce the number of steps for key intermediates to decrease the timeline for immediate scale up ensuring enough material is available for completion of medicinal chemistry activity
  • Reduction in the cost of intermediates during early screening and elimination of chemistry scale up issues from critical path during SAR studies
  • Business Model – short term FTE (1 FTE/ route)
  • Deliverable – Scalable Route + PoC (1-10g)